MedTrace Logo

Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients

NCT01508117 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2017-09-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the addition of an investigational medication, axitinib, to radiation therapy will improve the outcome of treatment in patients, above the age of 70.

Conditions

Interventions

DRUG

Axitinib

5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity

RADIATION

Radiation Therapy

45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Rekha Chaudhury, MD · University of Cincinnati

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01508117 on ClinicalTrials.gov